RISKS AND BENEFITS OF ORAL HORMONAL CONTRACEPTION
Abstract
Background: Oral hormonal contraception (OC) or the birth control pill that has been in use since 1960 is considered an efficient and reliable method of pregnancy prevention. In the early days the pill contained high doses of hormones, and the related complications were frequently reported. The composition of the pill has substantially changed, estrogen dose has been significantly decreased and so has the incidence of side effects.
Despite the reduced estrogen dose, the risk for the development of vein thromboembolism has not significantly decreased, as the final effect depends on the interaction with the progestage+n component. The OC use is in itself an independent risk factor for the develop- ment of ischemic stroke event (RR = 1.5), and for the development of myocardial infarction (RR = 1.84). Recent studies show that second generation OC users were at a higher risk of cardiovascular disease than the third generation OC users. The risk of breast cancer is also marginally increased (RR = 1.09-fold increased risk). The discussion about an association between the development of cervical cancer and an increased incidence of the disease in OC users is inclined to attribute this increased incidence to human papilloma virus infec- tion rather than to OC use. Beneficial effects of OC use are manifested through decreased incidence of endometrial cancer, which is mostly true in women with a lower body mass index (BMI). Additionally, OC plays a protective role in the development of ovarian cancer; recent studies have reported that OC use has prevented 200 000 ovarian cancers and 100 000 deaths from the disease. Also, the risk of colorectal cancer is OC users is lower (RR = 0.72).
Conclusions: Modern third generation OC preparations containing desogestrel and gestodene are a safe contraceptive method for all women except for those at increased risk of vein thrombosis.
Downloads
References
Burkman RT. Oral contraceptive: Current Status. In: Archer DF (ed.) Contracpetion for the 21st century. Clin Obstet Gynecol 2001; 44: 62-72.
Steinberg WM. Oral contraceptive user compliance: How to improve it. Gynecol Endocrinol 1995; 9(Suppl. 1): 1-4.
WHO Working Group. Cardiovascular Disease and Steroid Hormone Contraception. Geneve: World Health Organization, 1998.
Ursin G, Peters RK, Henderson BE, Ablaing G, Monroe KR, Pike MC. Oral contraceptive use and adenocarcinoma of cervix. Lancet 1994; 344: 1390-4.
GammbrellRD.Theroleofhormonesinetiologyandprevention of endometrial cancer . Clin Obstet Gynaecol 1986; 13: 695723.
Sperof L, Darney PD. A Clinical Guide for Contraception. 3rd Edition. Philadelphia, USA: Lippincontt, Williams and Wilkins, 2001.
Walker GR, Schlesselman JJ, Ness RB. Family history of cancer, oral contraceptive use and ovarian cancer risk: Am J Obstet Gynecol 2002; 186: 8-14.
CokerAL,HarkapS,FormeyJA:Oralcontraceptivesandreproduc- tive cancers: Weighing the risk and benefits. Fam pPlann Perspect 1993; 25: 17-21.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.